GC
DNA.WS

Guggenheim Capital’s Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share DNA.WS Stock Holding History

Guggenheim Capital’s Portfolio DNA.WS Stock Details DNA.WS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-399,600
Closed -$11.3K – 1957
2024
Q2 		$11.3K Hold
399,600
– – ﹤0.01% 1857
2024
Q1 		$36K Hold
399,600
– – ﹤0.01% 1865
2023
Q4 		$42.1K Hold
399,600
– – ﹤0.01% 1868
2023
Q3 		$89.9K Sell
399,600
-39,560,400
-99% -$10.6M ﹤0.01% 1810
2023
Q2 		$0 Buy
39,960,000
+39,560,400
+9,900% +$7.71M ﹤0.01% 1959
2023
Q1 		$71.9K Buy
399,600
+7,198
+2% +$1.65K ﹤0.01% 1897
2022
Q4 		$78.5K Sell
392,402
-4,869,298
-93% -$2.09M ﹤0.01% 1885
2022
Q3 		$0 Sell
5,261,700
-34,748,700
-87% -$23.8M ﹤0.01% 2073
2022
Q2 		$0 Buy
40,010,400
+39,609,148
+9,871% +$25.1M ﹤0.01% 2159
2022
Q1 		$353K Hold
401,252
– – ﹤0.01% 1816
2021
Q4 		$899K Hold
401,252
– – ﹤0.01% 1415
2021
Q3 		$1.36M Buy
+401,252
New +$1.43M 0.01% 1259

Other funds holding DNA.WS

AS
Altshuler Shaham Tel Aviv, Israel $5.54B AUM 44.68% 1-Year Est. Return
SBLIC
Security Benefit Life Insurance Company Topeka, Kansas $182M AUM 31.21% 1-Year Est. Return
HIA
Harbor Investment Advisory Lutherville, Maryland $1.43B AUM 30.71% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Guggenheim Capital's DNA.WS Position: Q3 2024 in Review

Guggenheim Capital sold out of Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share (DNA.WS) in Q3 2024, closing a stake of 399,600 shares — an estimated $11.3K sold.

Guggenheim Capital first reported a position in DNA.WS in Q3 2021 and held it in 12 quarters. The position peaked at $1.36M in Q3 2021. 5 funds tracked by Wall St. Rank hold DNA.WS as of Q3 2024.

  • Guggenheim Capital reported no remaining Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share position as of Q3 2024 after selling out during the quarter.
  • Guggenheim Capital sold 399,600 Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share shares in Q3 2024, an estimated $11.3K.
  • Guggenheim Capital first reported a position in Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share in Q3 2021 and held it in 12 quarters.
  • Guggenheim Capital's Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share position peaked at $1.36M in Q3 2021.
  • 5 funds tracked by Wall St. Rank held Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share as of Q3 2024.

Based on Guggenheim Capital's 13F filing for Q3 2024, filed 13 Nov 2024.